Dr. Boulmay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Canal St
New Orleans, LA 70112Phone+1 504-702-3697Fax+1 504-702-5724
Education & Training
University of FloridaFellowship, Hematology and Medical Oncology, 2005 - 2008- University of FloridaResidency, Internal Medicine, 2002 - 2005
LSU School of Medicine in ShreveportClass of 2002
Certifications & Licensure
LA State Medical License 2008 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Publications & Presentations
PubMed
- 252 citationsDurable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar
Journal of Clinical Oncology. 2018-06-01 - 64 citationsThree-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar
Journal for Immunotherapy of Cancer. 2021-04-01 - 11 citationsSmall cell lung cancer: time to diagnosis and treatment.Niaz Haque, Amer Raza, Robin McGoey, Brian Boulmay, Lisa Diethelm
Southern Medical Journal. 2012-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
